Immunotherapy in Acute Leukemias: Implications and Perspectives Using Wt1 Antigen.

Autor:	Cebinelli GC; Laboratory of Molecular Genetics and Immunology, Biological Sciences Center, State University of Londrina, Londrina-Paraná, Brazil., DE Sousa Pereira N; Laboratory of Studies and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Londrina-Paraná, Brazil., Sena MM; Laboratory of Molecular Genetics and Immunology, Biological Sciences Center, State University of Londrina, Londrina-Paraná, Brazil., DE Oliveira CE; Laboratory of Studies and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Londrina-Paraná, Brazil., Fujita TC; Laboratory of Studies and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Londrina-Paraná, Brazil., DA Rocha SP; Laboratory of Bacteriology, Department of Microbiology, Biological Sciences Center, State University of Londrina, Londrina-Paraná, Brazil., DE Abreu Oliveira FJ; Laboratory of Experimental Parasitology, Biological Sciences Center, State University of Londrina, Londrina-Paraná, Brazil., Marinello PC; Laboratory of Experimental Pathology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, Londrina-Paraná, Brazil., Watanabe MA; Laboratory of Studies and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Londrina-Paraná, Brazil maewatuel@gmail.com.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2016 Aug; Vol. 36 (8), pp. 3795-802.
Abstrakt:	The WT1 gene encodes a transcription factor involved in regulation of many cellular processes, including proliferation, differentiation, mRNA processing and apoptosis, besides acting as a transcription repressor of growth factors and their receptors' genes. This gene is expressed at high levels in several types of cancers, including acute leukemias. In this regard, many studies have identified WT1 protein as a tumor antigen, considered a target molecule for clinical application in human acute leukemias. Immunotherapy using WT1 antigen has been effective in stimulating immune responses against leukemic cells. Regarding adoptive immunotherapy, the use of dendritic cells (DCs) for the WT1-specific cytotoxic T cells generation proved to be efficient in the development and maintenance of immunologic cells. Therefore, these therapeutic methods, that provided enthusiasm for moving ahead, highlight several opportunities and challenges to be used in clinical practice for managing acute leukemias. (Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu